J Med Genet:脑胶质瘤遗传变异

2012-07-06 Beyond 生物谷

近日,Moffitt癌症中心发表研究证实脑胶质瘤疾病中存在罕见的遗传基因变异。 Moffitt癌症中心研究人员证实一种罕见的遗传变异与脑胶质瘤风险有关,脑胶质瘤是脑肿瘤的最常见和最致命的类型之一。研究发现一个罕见的遗传性变异和胶质瘤患者生存率的改善有关联。 这项研究首次证实脑胶质瘤的中一种罕见的易感性变异,将发表在最近一期??的Journal of Medical Genetics杂志上。

近日,Moffitt癌症中心发表研究证实脑胶质瘤疾病中存在罕见的遗传基因变异。

Moffitt癌症中心研究人员证实一种罕见的遗传变异与脑胶质瘤风险有关,脑胶质瘤是脑肿瘤的最常见和最致命的类型之一。研究发现一个罕见的遗传性变异和胶质瘤患者生存率的改善有关联。

这项研究首次证实脑胶质瘤的中一种罕见的易感性变异,将发表在最近一期​​的Journal of Medical Genetics杂志上。

脑胶质瘤是一种我们了解较少的肿瘤类型之一,其发病率较高、患者最终结果不容乐观。研究主要领导者癌症流行病学部副主席Kathleen M. Egan理学博士说: TP53基因变异rs78378222与胶质瘤相关性的发现为进一步了解这些肿瘤提供了新见解。

据作者表示,TP53是一个重要的抑癌基因基因,这项研究主要集中于TP53的单核苷酸多态性rs78378222。SNP破坏TP53的信号,因为SNP的活性一直与多种癌症有关。这项研究证实了rs78378222存在于致命的脑胶质瘤中。

研究人员进行的一个大型临床为基础的研究中,涉及到18岁或年龄更大的最近被确诊为脑胶质瘤的患者。结果发现共有566例胶质瘤和603名对照人员存在rs78378222变种基因分型。

研究结果表明,罕见的变异等位基因携带者发展罹患胶质瘤的几率增加3.5倍。然而,当研究人员审查rs78378222对生存的影响时,结果发现等位基因携带者的死亡率减少约50%。

这项研究由国家癌症研究所、美国卫生部以及Moffitt和Vanderbilt-Ingram癌症中心R01CA11674项目资助。

doi:10.1136/jmedgenet-2012-100941
PMC:
PMID:

Rare TP53 genetic variant associated with glioma risk and outcome

Kathleen M Egan, L Burton Nabors, Jeffrey J Olson, Alvaro N Monteiro, James E Browning, Melissa H Madden, Reid C Thompson

Validation of a recent finding linking a rare variant in TP53 to the risk of glioma, the most common primary brain tumour, is reported here. This study genotyped the single nucleotide polymorphism (SNP) rs78378222 in 566 glioma cases and 603 controls. The variant ‘C’ allele (with an allelic frequency of 1.1% in controls) was associated with a 3.5-fold excess in glioma risk (odds ratio 3.54; p=0.0001). Variant carriers had significantly improved survival (hazard ratio 0.52; p=0.009) when compared to non-carriers. The rs78378222 SNP is the first confirmed rare susceptibility variant in glioma. Results may shed light on the aetiology and progression of these tumours.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2013-01-24 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2013-03-08 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1733603, encodeId=e9bc1e33603cd, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jan 24 04:10:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048458, encodeId=f885204845807, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Mar 08 13:10:00 CST 2013, time=2013-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685864, encodeId=e5541685864eb, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 08:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342254, encodeId=ea9613422546e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377154, encodeId=627913e715429, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605777, encodeId=b6f31605e7757, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]

相关资讯

Blood:PTPN22激活AKT促进白血病细胞生存

磷酸酶PTPN22多态性变异已与多种自身免疫性疾病风险增加有关。近日,一项刊登在Blood杂志上的研究表明,PTPN22在慢性淋巴细胞白血病(CLL)中也过度表达。 慢性淋巴细胞白血病属慢性淋巴细胞恶性克隆性疾病。多起源于B细胞的恶性转化,淋巴细胞分化受阻于未成熟阶段,易伴发自身免疫病和低丙球蛋白血症。 研究证实,过度表达的PTPN22通过阻断B细胞受体(BCR)负调控细胞生存的信号通路,显著

J Mol Cell Biol:徐鹰等发现低氧可以驱动癌症生长

Journal of Molecular Cell Biology(《分子细胞生物学报》)2012年第3期“复杂疾病的系统生物学研究”专辑中发表了一篇美国佐治亚大学生物化学与分子生物学系徐鹰教授关于“Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive

英发现与口腔癌相关蛋白质

  英国研究人员最近发现了一种在口腔癌中起关键作用的蛋白质,以它为靶点进行治疗可以延长患癌实验鼠的生命,该发现有望为人类带来口腔癌新疗法。   英国癌症研究会等机构的研究人员在美国新一期《癌症研究》杂志上报告说,他们发现名为FRMD4A的蛋白质在口腔癌中起着关键作用。这种蛋白质会促进癌细胞生长,机体中这种蛋白质的含量越高,癌症就越容易扩散,或是越容易在治疗后复发。   研究人员接下来开展的动物

Cancer Res:英研究发现与口腔癌相关蛋白质

近日,英国研究人员发现了一种在口腔癌中起关键作用的蛋白质,以它为靶点进行治疗可以延长患癌实验鼠的生命。这一发现有望为人类带来口腔癌新疗法。 英国癌症研究会等机构的研究人员在美国新一期《癌症研究》(Cancer Research)杂志上报告说,他们发现名为FRMD4A的蛋白质在口腔癌中起着关键作用。这种蛋白质会促进癌细胞生长,机体中这种蛋白质的含量越高,癌症就越容易扩散,或是越容易在治疗后复发。

鹰嘴豆可提取抗肿瘤蛋白质和多肽

        记者近日从中科院新疆理化技术研究所获悉,该所资源化学研究室的科研人员研制出一种从鹰嘴豆豆瓣中提取天然抗肿瘤活性蛋白质和多肽的方法。相关研究成果日前获国家发明专利授权。   目前,肿瘤已成为仅次于心脑血管疾病的第二大杀手,寻找高效、低毒的抗肿瘤药物成为世界范围内相关研究的热点之一。生物活性肽是一类天然存在于动、植物和微生物等生物体内的多功能化合物。动、植物蛋白质经过蛋白酶解以及

PLoS ONE:阻断FGFR抑制肿瘤转移

成纤维细胞生长因子受体(FGFR)对肿瘤的生长和癌症病人的生存起着至关重要的作用。相比于其他受体酪氨酸激酶,科学家也一直将成纤维细胞生长因子(成纤维细胞生长因子)作为一种治疗癌症的靶标来开展研究。 近日,研究发现FGFR信号抑制后对原位乳腺66c14癌模型肿瘤生长、转移和淋巴血管形成的影响。体外研究表明FGFR抑制后,66c14细胞增殖比对照组慢。小鼠植入FGFR表达抑制的肿瘤细胞后,66c14